Metabolomics Insights Into Pathophysiological Mechanisms of Interstitial Cystitis

다국어 초록 (Multilingual Abstract)

Interstitial cystitis (IC), also known as painful bladder syndrome or bladder pain syndrome, is a chronic lower urinary tract syndrome characterized by pelvic pain, urinary urgency, and increased urinary frequency in the absence of bacterial infection or identifiable clinicopathology. IC can lead to long-term adverse effects on the patient’s quality of life. Therefore, early diagnosis and better understanding of the mechanisms underlying IC are needed. Metabolomic studies of biofluids have become a powerful method for assessing disease mechanisms and biomarker discovery, which potentially address these important clinical needs. However, limited intensive metabolic profiles have been elucidated in IC. The article is a short review on metabolomic analyses that provide a unique fingerprint of IC with a focus on its use in determining a potential diagnostic biomarker associated with symptoms, a response predictor of therapy, and a prognostic marker.

참고문헌 (Reference)

1 유성용, "‘Omics’ Approaches to Understanding Interstitial Cystitis/Painful Bladder Syndrome/Bladder Pain Syndrome" 대한배뇨장애요실금학회 16 (16): 159-168, 2012

2 Kim J, "p53 mediates interstitial cystitis antiproliferative factor (APF)-induced growth inhibition of human urothelial cells" 581 : 3795-3799, 2007

3 Ottem DP, "What is the value of cystoscopy with hydrodistension for interstitial cystitis?" 66 : 494-499, 2005

4 Liu HT, "Urinary nerve growth factor levels in overactive bladder syndrome and lower urinary tract disorders" 109 : 862-878, 2010

5 Anger JT, "Treatment choice, duration, and cost in patients with interstitial cystitis and painful bladder syndrome" 22 : 395-400, 2011

6 Van QN, "The use of urine proteomic and metabonomic patterns for the diagnosis of interstitial cystitis and bacterial cystitis" 19 : 169-183, 2003

7 Parsons CL, "The role of urinary potassium in the pathogenesis and diagnosis of interstitial cystitis" 159 : 1862-1866, 1998

8 Phatak S, "The management of interstitial cystitis: an update" 3 : 45-53, 2006

9 Landis JR, "The MAPP research network: design, patient characterization and operations" 14 : 58-, 2014

10 Clemens JQ, "The MAPP research network: a novel study of urologic chronic pelvic pain syndromes" 14 : 58-, 2014

11 Kohl SM, "State-of-the art data normalization methods improve NMR-based metabolomic analysis" 8 (8): 146-160, 2012

12 Zhang A, "Serum metabolomics as a novel diagnostic approach for disease: a systematic review" 404 : 1239-1245, 2012

13 Robledo VR, "Review of the CE-MS platform as a powerful alternative to conventional couplings in bio-omics and target-based applications" 35 : 2292-2308, 2014

14 Zhang CO, "Regulation of tight junction proteins and bladder epithelial paracellular permeability by an antiproliferative factor from patients with interstitial cystitis" 174 : 2382-2387, 2005

15 Ryan D, "Recent and potential developments in the analysis of urine: a review" 684 : 8-20, 2011

16 Yang W, "Quantitative proteomics identifies a beta-catenin network as an element of the signaling response to Frizzled-8 protein-related antiproliferative factor" 10 : M110.00749-, 2011

17 Serkova NJ, "Quantitative analysis in magnetic resonance spectroscopy: from metabolic profiling to in vivo biomarkers" 4 : 321-341, 2012

18 Nair M, "Prognostic and predictive biomarkers in cancer" 14 : 477-504, 2014

19 Kuo HC, "Potential urine and serum biomarkers for patients with bladder pain syndrome/interstitial cystitis" 21 (21): 34-41, 2014

20 Tamaki M, "Possible mechanisms inducing glomerulations in interstitial cystitis: relationship between endoscopic findings and expression of angiogenic growth factors" 172 : 945-948, 2004

21 Veselkov KA, "Optimized preprocessing of ultra-performance liquid chromatography/mass spectrometry urinary metabolic profiles for improved information recovery" 83 : 5864-5872, 2011

22 Ochodnický P, "Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target" 30 : 1227-1241, 2011

23 Krumsiek J, "Mining the unknown: a systems approach to metabolite identification combining genetic and metabolic information" 8 : e1003005-, 2012

24 Suhre K, "Metabolic profiling in diabetes" 221 : R75-R85, 2014

25 Zhou B, "MetaboSearch: tool for mass-based metabolite identification using multiple databases" 7 : e40096-, 2012

26 Li J, "Inflammation in the uterus induces phosphorylated extracellular signal-regulated kinase and substance P immunoreactivity in dorsal root ganglia neurons innervating both uterus and colon in rats" 86 : 2746-2752, 2008

27 Kiuchi H, "Increased vascular endothelial growth factor expression in patients with bladder pain syndrome/interstitial cystitis : its association with pain severity and glomerulations" 104 : 826-831, 2009

28 Zheng C, "Identification and quantification of metabolites in (1)H NMR spectra by Bayesian model selection" 27 : 1637-1644, 2011

29 Kim J, "Heparin-binding epidermal growth factor-like growth factor functionally antagonizes interstitial cystitis antiproliferative factor via mitogen-activated protein kinase pathway activation" 103 : 541-546, 2009

30 Persu C, "From interstitial cystitis to chronic pelvic pain" 3 : 167-174, 2010

31 Chung SD, "Elevation of serum c-reactive protein in patients with OAB and IC/BPS implies chronic inflammation in the urinary bladder" 30 : 417-420, 2011

32 Yoshimura N, "Editorial comment from Dr. Yoshimura to Potential urine and serum biomarkers for patients with bladder pain syndrome/interstitial cystitis" 21 (21): 42-, 2014

33 Hanno P, "Editorial comment from Dr. Hanno to Potential urine and serum biomarkers for patients with bladder pain syndrome/interstitial cystitis" 21 (21): 41-, 2014

34 NR Srinivas, "Do not just do it, do it right: urinary metabolomics -establishing clinically relevant baselines" Wiley-Blackwell 28 (28): 1491-1501, 2014

35 Keay S, "Decreased in vitro proliferation of bladder epithelial cells from patients with interstitial cystitis" 61 : 1278-1284, 2003

36 Evans RJ, "Current diagnosis of interstitial cystitis: an evolving paradigm" 69 (69): 64-72, 2007

37 Keay S, "Concentrations of specific epithelial growth factors in the urine of interstitial cystitis patients and controls" 158 : 1983-1988, 1997

38 Johansson SL, "Clinical features and spectrum of light microscopic changes in interstitial cystitis" 143 : 1118-1124, 1990

39 Keay S, "Cell signaling in interstitial cystitis/painful bladder syndrome" 20 : 2174-2179, 2008

40 Heemskerk AA, "CE-ESI-MS for bottom-up proteomics: Advances in separation, interfacing and applications" 2014

41 Hughes C, "Assessing the challenges of Fourier transform infrared spectroscopic analysis of blood serum" 7 : 180-188, 2014

42 Gebregiworgis T, "Application of NMR metabolomics to search for human disease biomarkers" 15 : 595-610, 2012

43 Keay S, "Antiproliferative factor, heparin-binding epidermal growth factor-like growth factor, and epidermal growth factor: sensitive and specific urine markers for interstitial cystitis" 57 (57): 104-, 2001

44 김자영, "Antiproliferative Factor Signaling and Interstitial Cystitis/Painful Bladder Syndrome" 대한배뇨장애요실금학회 15 (15): 184-191, 2011

45 Hanno PM, "Analysis of long-term Elmiron therapy for interstitial cystitis" 49 (49): 93-99, 1997

46 Kim J, "An hTERT-immortalized human urothelial cell line that responds to anti-proliferative factor" 47 : 2-9, 2011

47 Keay SK, "An antiproliferative factor from interstitial cystitis patients is a frizzled 8 protein-related sialoglycopeptide" 101 : 11803-11808, 2004

48 Kilpatrick LA, "Alterations in resting state oscillations and connectivity in sensory and motor networks in women with interstitial cystitis/painful bladder syndrome" 192 : 947-955, 2014

49 Cho K, "After the feature presentation: technologies bridging untargeted metabolomics and biology" 28 : 143-148, 2014

50 Wishart DS, "Advances in metabolite identification" 3 : 1769-1782, 2011

51 Zhang S, "Advances in NMR-based biofluid analysis and metabolite profiling" 135 : 1490-1498, 2010

52 Slobodov G, "Abnormal expression of molecular markers for bladder impermeability and differentiation in the urothelium of patients with interstitial cystitis" 171 : 1554-1558, 2004

53 Hanno PM, "AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome" 185 : 2162-2170, 2011

54 Fukui Y, "A metabonomic approach identifies human urinary phenylacetylglutamine as a novel marker of interstitial cystitis" 877 : 3806-3812, 2009

55 Keay S, "A diagnostic in vitro urine assay for interstitial cystitis" 52 : 974-978, 1988